1. Orlistat vs Mounjaro at a Glance
Orlistat and Mounjaro are both used to support weight loss, but they are fundamentally different medicines that work in completely different ways. Orlistat is a capsule that blocks some of the fat in your food from being absorbed. Mounjaro is a weekly injection that works on the appetite-regulating hormone system. Understanding that difference is the key to every other question on this page, including which might suit you, how their side effects differ, and whether they can ever be used together.
This guide compares the two fairly and without hype. It does not declare a winner, because the right choice depends entirely on your individual circumstances, your medical history and a proper clinical assessment. What it does do is set out the evidence clearly so you can have a well-informed conversation with a prescriber. If you want to explore the injectable option in more detail afterwards, our dedicated Mounjaro treatment page goes further, and our medically supervised weight loss hub covers a wider range of options.
Quick answer: Orlistat and Mounjaro are not the same. Orlistat (a lipase inhibitor) reduces fat absorption from food and is taken as a capsule with meals. Mounjaro (tirzepatide) is a once-weekly injection that reduces appetite by acting on GIP and GLP-1 receptors. In clinical trials tirzepatide has produced substantially greater average weight loss than orlistat, but it is a newer, prescription-only injectable with its own side effects and eligibility rules. Neither is universally "better" or "safer"; suitability depends on an individual clinical assessment.
1.1 Side-by-side comparison
| Feature | Orlistat | Mounjaro (tirzepatide) |
|---|---|---|
| Drug class | Lipase inhibitor | Dual GIP and GLP-1 receptor agonist |
| Manufacturer | Various (generic); branded as Xenical | Eli Lilly |
| How it works | Blocks absorption of some dietary fat in the gut | Reduces appetite and slows stomach emptying via hormone pathways |
| Form and use | Capsule, taken with meals up to three times daily | Once-weekly injection under the skin |
| Prescription status | Prescription (120mg) and lower-dose pharmacy versions (60mg) | Prescription only |
| Main side effects | Oily or fatty stools, urgent bowel movements, wind, stomach pain | Nausea, diarrhoea, constipation, vomiting, reduced appetite |
| Typical trial weight loss | Modest additional loss versus diet alone | Substantially greater average loss (see SURMOUNT-1 below) |
2. Is Orlistat the Same as Mounjaro?
No. This is one of the most common question, and the answer is a clear no. Orlistat and Mounjaro share only their broad goal of supporting weight loss; everything else is different.
Orlistat is a lipase inhibitor. It works locally in your digestive system, stopping the enzymes that break down dietary fat, so that roughly a third of the fat you eat passes through undigested rather than being absorbed. It does not act on your brain, and it does not affect appetite, making it distinct from an appetite suppressant. Orlistat is licensed for use in adults aged 18 and over .
Mounjaro is a brand of tirzepatide, a dual-acting agonist of two gut hormones, GIP and GLP-1. It works centrally on appetite and satiety, helping you feel fuller sooner and for longer, and it helps regulate blood sugar while slowing the rate at which your stomach empties. It is part of the newer generation of injectable weight loss medications, alongside treatments such as Wegovy.
So if you have seen these two names used interchangeably, they are not equivalent products. They are different drug classes, taken in different ways, with different evidence and different side-effect profiles.
Things to know:
- Orlistat acts in the gut on fat absorption; Mounjaro acts on appetite hormones.
- Orlistat is a capsule; Mounjaro is a weekly injection.
- Both still require a healthy, reduced-calorie diet and more activity to work well.
- Neither replaces professional medical advice about which, if either, is right for you.
3. How Each Treatment Works
3.1 How orlistat works: fat absorption explained
Orlistat binds to the lipase enzymes in your stomach and small intestine that normally digest fat. With those enzymes partly blocked, about a third of the fat from your food is not absorbed and is instead passed out in your stools. Because it works on food that is actually present, it is taken with meals, up to three times a day, and it has little effect on meals that contain very little fat. This mechanism is also why its side effects are so closely tied to how much fat you eat.
3.2 How Mounjaro works
Mounjaro contains tirzepatide, which activates both the GIP and GLP-1 receptors, including pathways linked to glucose-dependent insulinotropic polypeptide. In practical terms it supports appetite suppression, increases the feeling of fullness after eating, and slows gastric emptying. Many people report feeling fuller sooner and being satisfied with smaller portions, while its hormone effects can also support blood sugar regulation and may be relevant for people managing insulin resistance . Because it is a hormone-based treatment given by weekly injection, its effects build up gradually as the dose is increased over time under prescriber supervision. People with diabetes may also need a medication review because weight loss and changes in glucose control can increase the risk of low blood sugar, particularly when used alongside certain diabetes medicines . You can read more about how the injectable pathway works on our prescription weight loss treatments hub.
4. Weight Loss Effectiveness: Is Orlistat as Good as Mounjaro?
The question arises, which one works better. The honest, evidence-based position is that the two work through different pathways, with Mounjaro acting on GLP-1 and glucose-dependent insulinotropic polypeptide receptors, and they have very different levels of trial-demonstrated weight loss. In practice, effectiveness is often discussed as appetite suppression, while these pathways also support blood sugar regulation, and outcomes are commonly measured as a percentage of total body weight lost from a person’s starting body weight to judge whether treatment has led to significant weight loss. People with diabetes may need monitoring, as improved insulin sensitivity and weight loss can increase the risk of low blood sugar when other glucose-lowering treatments are involved.
4.1 What the Mounjaro evidence shows
The pivotal trial for tirzepatide in weight management was SURMOUNT-1, published in the New England Journal of Medicine, where effectiveness was usually measured as the percentage of total body weight lost from the starting body weight. It randomised 2,539 adults with obesity, or overweight with a weight-related complication, and ran for 72 weeks. Average weight reductions were 16.0% on the 5mg dose, 21.4% on 10mg and 22.5% on 15mg, compared with 2.4% on placebo. In the same trial, around 96% of participants on the higher doses lost at least 5% of their body weight, and a substantial proportion lost 20% or more, showing different levels of trial-demonstrated weight loss and the potential for some people to experience significant weight loss. These are among the largest average reductions reported for a medical (non-surgical) weight-loss treatment.
4.2 What the orlistat evidence shows
Orlistat has a long track record but a more modest effect. It is designed to support weight loss alongside diet and exercise rather than the larger average reductions seen with tirzepatide in clinical trials . UK prescribing practice reflects this: national guidance advises that orlistat should not be continued beyond three months unless a person has lost at least 5% of their body weight, which sets a realistic bar for what the medicine is expected to achieve. Across SURMOUNT-1, participants on tirzepatide lost about 20.9% of total body weight on average overall. For some people, the more modest weight loss associated with orlistat may be appropriate when combined with lifestyle change .
4.3 Putting effectiveness in context
On trial averages, tirzepatide produces considerably greater weight loss than orlistat. However, "as good as" depends on the individual. Orlistat is taken only when needed with meals, avoids injections, and has no effect on appetite hormones, which some people prefer. Mounjaro requires eligibility, a weekly injection and dose escalation. Results vary between individuals, and your prescriber will determine which treatment, if any, is appropriate for you. That matters when comparing different weight loss medications, because the right choice depends on your goals, medical history, and how you want to approach weight management. In some cases, people may prefer a more gradual approach to weight management, so orlistat may suit those looking for an alternative alongside lifestyle change .
| Evidence point | Orlistat | Mounjaro (tirzepatide) |
|---|---|---|
| Key trial context | Modest additional loss vs diet; 5% at 3 months review benchmark | SURMOUNT-1: 2,539 adults, 72 weeks |
| Average weight loss | Modest | 16.0% to 22.5% by dose vs 2.4% placebo |
| Route | Oral capsule with meals | Weekly subcutaneous injection |
| Best thought of as | A support to diet and exercise | A more intensive medical weight-loss option |
5. Side Effects: Is Orlistat Safer Than Mounjaro?
"Safer" is not a simple yes or no, because the two medicines carry different types of risk rather than more or less of the same risk. A fair comparison looks at what kind of side effects each tends to cause and how they are managed.
5.1 Comparison of orlistat side effects and fat soluble vitamins
Orlistat's side effects are almost all gastrointestinal and are a direct result of unabsorbed fat passing through the gut. They commonly include oily or fatty stools, more frequent and sometimes urgent bowel movements, wind that may be accompanied by an oily discharge, and stomach pain. These effects are usually more pronounced after high-fat meals and tend to settle when the diet is kept lower in fat. They are predictable and, for many people, controllable through food choices.
To use orlistat safely, patients should review other medicines with a prescriber because reduced fat absorption can affect the absorption of some medicines and vitamins and may affect nutritional status .
Orlistat should not generally be used during pregnancy, and its use during breastfeeding should be discussed with a healthcare professional .
5.2 Mounjaro side effects
Mounjaro's most common side effects are also digestive but arise through a different mechanism. They include nausea, diarrhoea, constipation, vomiting, reduced appetite, and stomach pain or abdominal discomfort, and they are often most noticeable when the dose is first increased . For most people, Mounjaro-related digestive side effects ease over time as the body adjusts. With orlistat, gastrointestinal side effects often improve when it is used alongside a lower-fat diet . Because it is a more systemic treatment, it also carries specific cautions, for example around a personal or family history of certain thyroid cancers and a history of pancreatitis, which is why a thorough clinical assessment is essential before starting.
5.3 Serious effects and when to seek help
Both medicines have rarer but more serious potential effects. With orlistat, seek medical advice for signs of liver problems such as yellowing of the skin or eyes, severe abdominal pain, or symptoms suggestive of gallstones or kidney stones . With Mounjaro, seek urgent help for severe, persistent abdominal pain that may spread to the back (a possible sign of pancreatitis), signs of an allergic reaction, or symptoms of gallbladder problems. This medicine should only be used under the supervision of an appropriately qualified prescriber, who will explain the full warning signs to watch for and when to seek guidance.
| Side-effect dimension | Orlistat | Mounjaro (tirzepatide) |
|---|---|---|
| Most common effects | Oily stools, urgency, wind, cramping | Nausea, diarrhoea, constipation, vomiting |
| Main driver | Unabsorbed dietary fat | Appetite-hormone action and slowed digestion |
| Typical pattern | Linked to fat intake; eases with lower-fat diet | Often worse at dose increases; eases over time. If vomiting or diarrhoea occurs and you rely on oral contraceptives, check your prescriber's advice. |
| Key cautions | Liver and gallbladder symptoms | Pancreatitis, thyroid history, gallbladder |
Rather than declaring one categorically safer, the sensible reading is that orlistat's risks are mostly local and diet-related, while Mounjaro's are more systemic but well characterised. Your prescriber will weigh these against your personal health profile, especially if you experience rapid weight loss or warning signs that could affect nutrition and maintaining essential bodily functions. In that situation, prompt review matters because nutrient shortfalls can interfere with essential bodily functions.
6. Can You Take Orlistat and Mounjaro Together?
This is a frequent and important question, and it deserves a careful answer. Orlistat and Mounjaro are not a standard combined therapy, and you should not start taking them together on your own initiative.
Interaction resources list a moderate interaction between the two. The concern is not that they chemically clash in a dangerous way, but that weight loss and changes in fat absorption from orlistat can alter how much tirzepatide a person needs, which is particularly relevant for anyone whose blood sugar is being managed. That can mean a need for closer monitoring and adjustment. Because both medicines also act on the digestive system, mounjaro and orlistat can mean some people experience digestive discomfort, especially if symptoms are already troublesome. If appetite is reduced while fat absorption is also reduced, there may be an increased risk of nutritional deficiencies . If you experience significant weight loss, treatment may need review sooner rather than later.
For these reasons, combining orlistat and Mounjaro is a decision that only an appropriately qualified prescriber should make and supervise, based on your individual clinical assessment. In practice, most people use one approach at a time. If you are already taking one and wondering about adding or switching to the other, speak to a prescriber first rather than combining them yourself.
Key takeaways on combining them:
- They are not a routine combination, and a moderate interaction is documented.
- Do not start both together without prescriber supervision.
- Overlapping digestive side effects are a realistic downside.
- A prescriber may occasionally manage a transition, but this is individualised.
- Seek guidance promptly if you experience unexpectedly rapid weight loss, worsening gastrointestinal symptoms, or signs of poor nutritional intake .
7. Switching From Orlistat to Mounjaro
Many people search for how to move from orlistat to Mounjaro, often because orlistat has produced only modest results or its dietary side effects have become hard to live with. Switching is common and generally straightforward, but it should be done through a proper assessment rather than by simply stopping one and starting the other.
A prescriber will typically review why orlistat is being stopped, confirm that you meet the eligibility criteria for tirzepatide, check your medical history for the specific cautions that apply to GLP-1 based treatments, and then start Mounjaro at a low introductory dose that is increased gradually. Because orlistat works only while you are taking it, its effect on fat absorption stops quickly once you stop the capsules, so there is no long "washout" period like in some other medicines. You can begin that conversation through an online clinical assessment, and our guide to buying Mounjaro online explains what the injectable pathway involves.
8. Eligibility and UK Access Pathways
Because these are different medicines, they have different routes to access in the UK.
8.1 Orlistat eligibility
On the NHS, orlistat may be considered for adults with a BMI of 30 or above, or a BMI of 28 or above if you also have weight-related conditions such as type 2 diabetes or high blood pressure. A lower-dose version (60mg) is available from pharmacies without a prescription for eligible adults . It is always intended to be used alongside a reduced-calorie, lower-fat diet and increased physical activity.
8.2 Mounjaro eligibility
Mounjaro's route on the NHS is governed by NICE Technology Appraisal TA1026, which is being rolled out in phases through primary care over several years. The core criteria involve a BMI of at least 35 together with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease), with the BMI threshold usually reduced by 2.5 for people from certain ethnic backgrounds. Early phases prioritise those with the highest BMI and the most comorbidities. Many people who do not yet qualify on the NHS choose a regulated private route instead, which has its own clinical eligibility check. Our weight management treatments hub explains the different pathways.
9. Cost and What to Check Before You Buy
Orlistat and Mounjaro sit at very different price points, which reflects their different nature. Orlistat is an established, relatively low-cost capsule, while Mounjaro is a newer branded injectable and costs considerably more per month. Prices change and vary by pharmacy and dose, so always check the current live price rather than relying on a figure quoted in an article.
Questions worth asking before you buy either medicine online:
- Is the pharmacy GPhC-registered, and is there genuine independent prescriber review rather than an instant sale?
- Is the medicine genuine and sourced through the regulated UK supply chain?
- What exactly is included in the price, and are there any additional consultation or delivery fees?
- For Mounjaro, is delivery handled appropriately, and is the product supplied with clear dosing and storage guidance?
- Is there ongoing support and follow-up, not just a one-off transaction?
For readers considering oral weight-management treatments, our guide explains how oral options compare with injectable treatments .
10. Which Might Be Right for You?
There is no universal answer, and by design this guide does not name a winner. The most useful way to think about it is in terms of fit.
Orlistat may appeal to someone who wants a non-injectable option, is comfortable following a lower-fat diet, and is looking for moderate support rather than dramatic change. Mounjaro may suit someone who meets the eligibility criteria, has struggled with appetite and portion control, and is comfortable with a weekly injection and closer monitoring .
The decision should always be made with a prescriber, who can weigh your BMI, medical history, previous attempts, preferences and any contraindications. Treatment suitability depends on an individual clinical assessment.
11. Key Takeaways
- Orlistat and Mounjaro are different medicines: a fat-absorption capsule versus an appetite-acting weekly injection.
- Mounjaro (tirzepatide) is made by Eli Lilly; orlistat is available as a generic and branded as Xenical.
- In SURMOUNT-1, tirzepatide produced average weight reductions of 16.0% to 22.5% by dose over 72 weeks; orlistat is associated with more modest average weight loss when used alongside diet and exercise .
- Orlistat's side effects are mainly diet-related and gastrointestinal; Mounjaro's are appetite-mediated and usually ease over time.
- They are not a routine combination, a moderate interaction is documented, and combining them needs prescriber supervision.
- Switching from orlistat to Mounjaro is common but should go through a clinical assessment.
- Neither is universally better or safer; the right choice is individual.
13. Medical Disclaimer
This article is for general information and education only. It does not constitute medical advice and is not a substitute for consultation with a qualified healthcare professional. It does not recommend any specific medicine, dose or combination. Treatment suitability depends on an individual clinical assessment, and these medicines should only be used under the supervision of an appropriately qualified prescriber. Results vary between individuals. Do not start, stop, combine or switch weight-loss medicines without professional advice. If you experience severe abdominal pain, signs of an allergic reaction, or other concerning symptoms, seek urgent medical advice. In an emergency, call 999 .
